Share-based Payment Arrangement, Expense of Esperion Therapeutics, Inc. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Esperion Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Esperion Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,349,000, a 22% decline year-over-year.
  • Esperion Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,288,000.
  • Esperion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11,993,000, a 0.29% increase from 2023.
  • Esperion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11,958,000, a 21% decline from 2022.
  • Esperion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,215,000.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Esperion Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,288,000 $2,349,000 -$673,000 -22% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $10,961,000 $2,669,000 -$262,000 -8.9% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $11,223,000 $2,465,000 -$770,000 -24% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $11,993,000 $2,805,000 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q3 2024 $3,022,000 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $2,931,000 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $3,235,000 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q1 2019 $6,400,000 +$600,000 +10% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q3 2018 $21,000,000 $5,300,000 +$400,000 +8.2% 01 Jul 2018 30 Sep 2018 10-Q 01 Nov 2018 2018 Q3
Q2 2018 $20,600,000 $5,500,000 +$700,000 +15% 01 Apr 2018 30 Jun 2018 10-Q 02 Aug 2018 2018 Q2
Q1 2018 $19,900,000 $5,800,000 +$1,700,000 +41% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $18,200,000 $4,400,000 +$900,000 +26% 01 Oct 2017 31 Dec 2017 10-K 20 Feb 2018 2017 FY
Q3 2017 $17,300,000 $4,900,000 +$1,300,000 +36% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $16,000,000 $4,800,000 +$800,000 +20% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $15,200,000 $4,100,000 -$400,000 -8.9% 01 Jan 2017 31 Mar 2017 10-Q 02 May 2018 2018 Q1
Q4 2016 $15,600,000 $3,500,000 01 Oct 2016 31 Dec 2016 10-K 20 Feb 2018 2017 FY
Q3 2016 $3,600,000 +$300,000 +9.1% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $4,000,000 +$1,100,000 +38% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $4,500,000 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q3 2015 $3,300,000 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $2,900,000 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2

Esperion Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $11,993,000 +$35,000 +0.29% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 $11,958,000 -$3,257,000 -21% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 $15,215,000 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2025 2024 FY
2017 $18,200,000 +$2,600,000 +17% 01 Jan 2017 31 Dec 2017 10-K 20 Feb 2018 2017 FY
2016 $15,600,000 +$3,000,000 +24% 01 Jan 2016 31 Dec 2016 10-K 20 Feb 2018 2017 FY
2015 $12,600,000 +$8,900,000 +241% 01 Jan 2015 31 Dec 2015 10-K 20 Feb 2018 2017 FY
2014 $3,700,000 +$2,500,000 +208% 01 Jan 2014 31 Dec 2014 10-K 22 Feb 2017 2016 FY
2013 $1,200,000 +$1,100,000 +1100% 01 Jan 2013 31 Dec 2013 10-K 25 Feb 2016 2015 FY
2012 $100,000 +$21,549 +27% 01 Jan 2012 31 Dec 2012 10-K 10 Mar 2015 2014 FY
2011 $78,451 01 Jan 2011 31 Dec 2011 10-K 13 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.